Mastodawn

🧪 A new liver- and gut-targeted oral drug has shown, in a first clinical trial, its ability to reduce triglycerides and other blood lipids - major risk factors for cardiovascular disease, stroke, and pancreatitis.

First-in-human drug trial lowers high blood fats

In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug can safely lower triglycerides and other blood lipids.